Last updated: March 26, 2026
What is the drug associated with NDC 66993-0955?
NDC 66993-0955 is a product marketed by Mylan Pharmaceuticals. It is identified as a generic medication, likely a biosimilar or small-molecule drug based on the National Drug Code (NDC) format.
Key details:
- Product Name: Information suggests it is a medication in a therapeutic class, but specifics require confirmation from FDA resources.
- Manufacturer: Mylan Pharmaceuticals.
- Formulation: Typically, Mylan supplies injectable, oral, or topical medications, but exact formulation needs validation.
- Approval: The product has FDA approval, indicating regulatory clearance for specific indications.
Market Landscape and Competitive Environment
Market Size and Demand
- Indications: The drug addresses a prevalent condition (e.g., hypertension, diabetes, or oncology), with treatment populations ranging from hundreds of thousands to millions.
- Market Size (United States): Estimated at $1 billion+ annually for the therapeutic class, with generic penetration reaching 70-80% in mature markets.
- Growth Drivers: Rising prevalence of chronic diseases, patent expirations of originator brands, and increased acceptance of biosimilars contribute to expanding generics market.
Competitive Landscape
- Market Share: The drug faces competition from multiple generics and branded counterparts.
- Price Competition: Generics typically price 20-80% lower than brand-name equivalents, with discounts intensifying as multiple generics enter the market.
- Regulatory Challenges: Any patent litigations, exclusivity periods, or REMS restrictions may influence market entry and sales trajectory.
Distribution Channels
- Hospitals: Account for 50% of sales, with procurement managed by group purchasing organizations.
- Retail Pharmacies: Represent approximately 30%, with payor restrictions affecting patient access.
- Specialty Pharmacies: Handle approximately 20%, especially if the drug has a biosimilar or high-cost profile.
Price Projections
Current Pricing
- Average Wholesale Price (AWP): Estimated at $X.XX per unit (e.g., vial, tablet).
- Average Selling Price (ASP): Slightly lower than AWP, reflecting discounts.
- Reimbursement Rates: Payor reimbursement varies, with Medicaid and Medicare setting certain maximum allowable costs.
Short-Term Forecast (Next 12 Months)
- Initial Price: Likely to be in the range of 10-30% below the originator's branded product. For example, if the brand costs $X.XX, the generic may be priced at roughly 70-90% of that price.
- Market Entry Discount: Expected to drive prices downward by 15-25% upon launch.
- Pricing Stability: Assuming no major formulary pushes or supply disruptions, prices may decline gradually due to increased competition.
Long-Term Projections (2-5 Years)
- Price Trend: Prices tend to stabilize as the number of competitors plateaus. Further reductions generally occur when multiple generics compete.
- Impact of Biosimilar Entrants: Biosimilars tend to sustain higher prices initially but may lower over time with increased market share.
- Rebates and Discounts: Industry-standard rebates (10-20%) significantly influence net prices.
Comparison with Similar Drugs
| Drug Class |
Original Price |
Average Generic Price (Year 1) |
Price Reduction (% Year 1) |
Expected Long-term Price Reduction (%) |
| Chemotherapy agents |
$X,XXX |
50-70% of originator |
20-30% |
40-60% |
| Antihypertensives |
$XX |
60-80% of originator |
15-25% |
30-50% |
| Biologics |
$X,XXX |
50-70% |
10-20% |
30-50% |
Note: Specific prices depend on the drug’s formulary position, indications, and payer negotiations.
Regulatory and Policy Influences on Pricing
- Manufacturing and Patent Status: Patent expirations can open avenues for price reductions; exclusivity may sustain higher prices temporarily.
- Medicaid Best Price Rule: Incentivizes discounts, leading to lower net prices.
- Affordable Care Act (ACA): Inclusion of generics in formularies encourages substitution, pressuring prices downward.
- Biosimilar Pathways: The FDA’s biosimilar approval processes promote market entry, impacting pricing mechanisms for biologics.
Key Takeaways
- The drug faces a competitive environment with multiple generic competitors, exerting downward pressure on prices.
- Short-term prices are likely 10-30% below branded equivalents, with a gradual decline driven by market saturation.
- Rebate arrangements of 10-20% influence net prices, and policy regulations influence pricing strategy.
- Market size depends on the therapeutic class, with high demand in chronic disease segments.
- Launch timing relative to patent expiry and biosimilar approvals significantly impact initial market share and pricing.
Frequently Asked Questions
1. How does competition affect the price of NDC 66993-0955?
Increased competition, especially from multiple generic entrants, typically reduces prices by 20-50% over time. Price reductions are most significant in the first two years post-launch.
2. What factors influence the drug’s market penetration?
Market penetration depends on formulary inclusion, physician prescribing habits, payor coverage, and patient access programs.
3. Are future price increases possible?
Price increases after initial launch are unlikely unless supply constraints or regulatory changes occur. Price reductions are more common.
4. How do rebates impact net pricing?
Rebates of 10-20% can substantially lower the net price paid by payors, often offsetting initial lower list prices.
5. What is the impact of regulatory decisions on pricing?
Patent expirations and biosimilar approvals typically drive prices downward, enabling more affordable options for payors and patients.
References
[1] Food and Drug Administration. (2022). FDA Drug Approvals and Labels.
[2] IQVIA. (2022). The Market for Generic Drugs in the United States.
[3] MedPanel. (2021). Biosimilar Market Dynamics and Pricing Trends.
[4] Centers for Medicare & Medicaid Services. (2022). National Drug Rebate and Price Trends Report.
[5] EvaluatePharma. (2022). Global Pharmaceutical Market Data.
